EGFR and non-small cell lung carcinoma: Moreover, numerous prospective studies, such as the phase II/III KEYNOTE-10 trial with pembrolizumab monotherapy [38], the phase I CheckMate012 trial with nivolumab [39], the phase III OAK [40] and the phase II BIRCH trials with atezolizumab [41], and the ATLANTIC trial with durvalumab [42], have consistently demonstrated a limited or absent benefit of immunotherapy compared with chemotherapy in previously treated EGFR-mutated NSCLC, together with several meta-analyses and retrospective studies [9,43,44] (Table 1).